Division of Health Care Finance
Landon State Office Building
900 SW Jackson, Suite 900 N
Topeka, Kansas 66612-1220

Kansas
Department of Health and Environment

Phone: 785-296-3981
Fax: 785-296-4813
www.kdheks.gov

Lee A. Norman, M.D., Secretary

Laura Kelly, Governor

Drug Utilization Review Board Meeting
Agenda, Open Session April 21, 2021
10:00 a.m. – 2:00 p.m.

Meeting Location*

*Due to COVID-19, this meeting will be held virtually. Please use the information below to join the meeting:
Public/Participant Line: Dial: (312) 626-6799, Meeting ID: 833 3485 2319
Zoom Meeting: https://us02web.zoom.us/j/83334852319

Members of the general public are required to complete a conflict of interest form if they intend to provide public comments to the Board. To assist the operator in coordinating public comment, completed forms are due 1 week prior to the meeting (April 14, 2021). Please email the completed form to Annette.Grant@ks.gov.

Board Members

Moneeshindra Mittal, MD
James Backes, PharmD
Jennifer Clair, MD
Katie Burenheide Foster, PharmD, MS, BCPS, FCCM
Kristen Powell, PharmD
Roger Unruh DO
LaTonyua Rice, PharmD, CGP
Arthur Snow, MD

KDHE-DHCF Staff

Annette Grant, RPh
Victor Nguyen, PharmD
Carol Arace, Administrative Specialist

Gainwell Technologies/KEPRO Staff

Karen Kluczykowski, RPh
Kathy Kaesewurm, RN, BSN
Christina Faulkner, PharmD, BCPS
Harry Vu, PharmD

MCO Staff

Mark DeMary, PharmD, **Aetna Better Health of Kansas**
Angie Yoo, PharmD, **Sunflower State Health Plan**
Bernadette Ueda, PharmD, **UnitedHealthcare Community Plan**

I. CALL TO ORDER

A. Announcements

This meeting will be operator-assisted. An opportunity for public comment was given at the top of the agenda.

II. OLD BUSINESS

A. Review and Approval of January 20, 2021 Meeting Minutes

III. NEW BUSINESS

A. Revised Prior Authorization (PA) Criteria

1. **Preferred Drug List**

   At the March 2021 PDL Committee meeting, the Committee reviewed and approved of the removal of the annual PA renewal from certain PDL classes.

   i. Revised PDL List
   ii. *Public Comment
   iii. Board Discussion

2. **Duchenne Muscular Dystrophy (DMD) Agents**

   This revision adds Amondys 45™ to the list of agents requiring prior authorization.

   i. Revised PA Criteria
   ii. *Public Comment
   iii. Board Discussion

3. **Ulcerative Colitis (UC) Agents**

   This revision updates dosing guidelines for Humira® and updates the FDA's safety communication for Xeljanz®.

   i. Revised PA Criteria
   ii. *Public Comment
   iii. Board Discussion

4. **Weight Loss Agents**

   This revision updates FDA-approved labeling changes for Saxenda®.

   i. Revised PA Criteria
   ii. *Public Comment
   iii. Board Discussion

5. **Hepatitis C Agents**

   This revision removes the sobriety requirement prior to treatment.

   i. Revised PA Criteria
   ii. *Public Comment
   iii. Board Discussion

B. **New Prior Authorization (PA) Criteria**

1. **Chimeric Antigen Receptor T-Cell (CAR-T) Therapy Agents**
   This revision consolidates the existing criteria for Kymriah®, Tecartus® and Yescarta® and adds criteria for the new agents Abecma® and Breyanzi®.
   i. Prior Authorization Criteria
   ii. *Public Comment
   iii. Board Discussion

2. **Hypercholesterolemia Agents**
   This revision includes consolidation of Juxtapid®, Praluent® and Repatha® criteria, removal of Kynamro® and addition of Evkeeza™, Nexletol™ and Nexlizet™.
   i. Prior Authorization Criteria
   ii. *Public Comment
   iii. Board Discussion

3. **Consent Agenda**
   This pre-management process is intended to streamline certain simple changes to certain existing PA criteria, including updates to Oncology Agents and Oncology – Auxiliary Treatment Agents. Changes to all other criteria include additions of new formulations/strengths/dosing regimens/biosimilars where the indications are the same.
   i. Revised PA Criteria
   ii. *Public Comment
   iii. Board Discussion

C. **Miscellaneous Items**

1. **Fee-for-Service Retrospective Drug Utilization Review Topic Selections**
   The DUR Board will select topics for the two (2) FFS RDUR interventions between May and July 2021.
   i. Topic Presentations
   ii. Board Discussion

IV. ADJOURN

The next DUR Board meeting is scheduled for July 21, 2021.

*Public comment is limited to five minutes per product; additional time will be allowed at the DUR Board's discretion. Informal comments will be accepted from members of the audience at various points in the agenda.

****THIS AGENDA IS SUBJECT TO CHANGE****